Chartwell Partners Recruits Christopher Morabito, MD, as Chief Medical Officer for Fulcrum Therapeutics

Rare disease-focused, Cambridge, MA-based biopharmaceutical company, Fulcrum Therapeutics (NASDAQ: FULC), named Chris Morabito, MD, as CMO. Dr. Morabito has extensive leadership experience at biotechnology and pharmaceutical companies, advancing drug discovery and clinical programs for numerous Phase 1, proof-of-concept, and pivotal studies. Most recently, he served as Chief Medical Officer at Cardurion Pharmaceuticals. Previously, he held leadership roles with Takeda, Sanofi, and Merck.